Was EU’s COVID-19 vaccine procurement strategy irrational? A re-analysis based on cost-effectiveness considerations

AIM: The European Union (EU) has received criticism for being slow to secure coronavirus disease (COVID-19) vaccine contracts in 2020 before the approval of the first COVID-19 vaccine. This study aimed to retrospectively analyze the EU’s COVID-19 vaccine procurement strategy. To this end, the study...

Descripción completa

Detalles Bibliográficos
Autor principal: Gandjour, Afschin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694594/
https://www.ncbi.nlm.nih.gov/pubmed/36434631
http://dx.doi.org/10.1186/s12913-022-08726-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694594/
https://www.ncbi.nlm.nih.gov/pubmed/36434631
http://dx.doi.org/10.1186/s12913-022-08726-4

Ejemplares similares